Article
Expression and localisation of VEGFA165b in eyes with retinal vein occlusion
Search Medline for
Authors
Published: | September 21, 2010 |
---|
Outline
Text
Background: In contrast to its splice variant VEGFA165, VEGFA165b acts as an anti-proliferative agent. The balance of VEGFA165b to VEGFA165 is shifted towards a proangiogenic state in angioproliferative diseases, such as proliferative diabetic retinopathy. The aim of our study was to examine the expression and localisation of VEGFA165b in the eye with a special focus on retinal vein occlusion.
Methods: Vitreous samples of patients with branch or central retinal vein occlusion (BRVO, resp. CRVO) were examined for the expression of VEGFA165b by means of ELISA and were compared to samples of patients with macular pucker as controls. The localisation of VEGFA165b in the eye was determined by immunohistological staining in eyes with different diseases, such as retinal vein occlusion or tumors.
Results: The balance of VEGFA165b to VEGFA165 was shifted towards VEGFA165 in patients with RVO. The effect was more pronounced in CRVO than in BRVO. In immunohistological stainings, VEGFA165b could be detected in the tunica media of arteries and retinal arterioles, as well as in inflamed areas and neural or glial cells.
Conclusions: The balance of VEGFA165b to VEGFA165 is shifted towards a proangiogenic state in vitreous samples of patients with RVO. The localisation of VEGFA165b resembles that of VEGFA165. Influencing the balance of VEGFA165b to VEGFA165 might be a feasible approach in patients with angioproliferative disease.